Bayer submits Biologics License Application in the U.S. for BAY94-9027 – a long-acting factor VIII for the treatment of Hemophilia A (for specialized target groups only)

Pivotal studies with BAY94-9027 showed that bleed protection was achieved with extended dosing intervals
Source: Bayer Company News - Category: Pharmaceuticals Source Type: news